Could a new drug combo tame pancreatic cancer and prevent clots?
NCT ID NCT07214298
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding pegcetacoplan to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Pegcetacoplan targets part of the immune system to possibly slow tumor growth and reduce blood clots, a common complication. About 35 adults with advanced pancreatic cancer will participate. The goal is to see if the combination improves survival and reduces clot-related risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pegcetacoplan (a complement inhibitor) combined with mFOLFIRINOX chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil)
What this could lead to
If it works, this could lead to a more effective treatment for metastatic pancreatic cancer and help prevent dangerous blood clots.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply to all patients. The combination may cause significant side effects, and the benefit is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••